Literature DB >> 9342888

The WHO Global Programme for Vaccines and Immunization Vaccine Trial Registry.

S E Robertson1, M V Mayans, S Horsfall, P F Wright, J Clemens, B Ivanoff, P H Lambert.   

Abstract

In 1995, the WHO Global Programme for Vaccines and Immunization established a Vaccine Trial Registry. As of September 1996, this registry included 50 WHO-supported vaccine trials, of which 25 (50%) were completed studies. The vaccines most frequently tested have been against measles (9 trials), poliovirus (8 trials), cholera (8 trials), enterotoxigenic Escherichia coli (4 trials), and pneumococcus (4 trials). Nearly 80% of these trials have been conducted in developing countries, with the largest number being in Africa. Among the 25 completed trials, outcomes measured were immune response (24 trials), adverse reactions (13 trials), morbidity (4 trials), and mortality (1 trial). WHO's contributions to these studies include direct funding, assistance with study design, site visits, data analysis, vaccine procurement, and vaccine potency testing.

Entities:  

Keywords:  Delivery Of Health Care; Economic Factors; Health; Health Services; Immunization; International Agencies; Organizations; Primary Health Care; Research Activities; Research And Development; Research Methodology; Technology; Un; Vaccination; Vaccines; Who

Mesh:

Substances:

Year:  1997        PMID: 9342888      PMCID: PMC2486974     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  23 in total

1.  Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine [corrected] for prevention of pneumonia and meningitis in Gambian infants.

Authors:  K Mulholland; S Hilton; R Adegbola; S Usen; A Oparaugo; C Omosigho; M Weber; A Palmer; G Schneider; K Jobe; G Lahai; S Jaffar; O Secka; K Lin; C Ethevenaux; B Greenwood
Journal:  Lancet       Date:  1997-04-26       Impact factor: 79.321

2.  The type and quality of randomized controlled trials (RCTs) published in UK public health journals.

Authors:  T Fahey; C Hyde; R Milne; M Thorogood
Journal:  J Public Health Med       Date:  1995-12

Review 3.  European Commission COST/STD Initiative. Report of the expert panel IV. A common European network for clinical trials.

Authors:  E R Moxon; R Clemens; P Druilhe; J Eskola; O Razum; J Van Hoof
Journal:  Vaccine       Date:  1996-05       Impact factor: 3.641

4.  Hand searching the Journal of Epidemiology and Community Health as part of th Cochrane Collaboration.

Authors:  R Milne; M Thorogood
Journal:  J Epidemiol Community Health       Date:  1996-04       Impact factor: 3.710

Review 5.  New lessons for rotavirus vaccines.

Authors:  R I Glass; J R Gentsch; B Ivanoff
Journal:  Science       Date:  1996-04-05       Impact factor: 47.728

6.  Evaluating new vaccines for developing countries. Efficacy or effectiveness?

Authors:  J Clemens; R Brenner; M Rao; N Tafari; C Lowe
Journal:  JAMA       Date:  1996-02-07       Impact factor: 56.272

7.  Immunization of 6 and 9 month old infants with AIK-C, Edmonston-Zagreb, Leningrad-16 and Schwarz strains of measles vaccine.

Authors:  V M Bolotovski; M Grabowsky; C J Clements; P Albrecht; E R Brenner; A I Zargaryantzs; S K Litvinov; I V Mikheyeva
Journal:  Int J Epidemiol       Date:  1994-10       Impact factor: 7.196

8.  The quest for trials on the efficacy of human vaccines. Results of the handsearch of Vaccine.

Authors:  T Jefferson; V Jefferson
Journal:  Vaccine       Date:  1996-04       Impact factor: 3.641

9.  Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.

Authors:  A Concha; A Giraldo; E Castañeda; M Martínez; F de la Hoz; F Rivas; A Depetris; A M Svennerholm; D A Sack
Journal:  Bull Pan Am Health Organ       Date:  1995-12

Review 10.  Vaccination against typhoid fever: present status.

Authors:  B Ivanoff; M M Levine; P H Lambert
Journal:  Bull World Health Organ       Date:  1994       Impact factor: 9.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.